MDXG
MIMEDX GROUP, INC.
Next earnings Jul 28, 2026 · consensus $-0.04 EPS, $64.7M rev
Last earnings -9.1% on 2026-04-29
$3.93
▲ +3.15%$3.93▼ -33.84%
over 1Y
L $3.09EODHDH $7.96
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.1%
1W+7.1%
1M+8.9%
3M+3.1%
YTD-39.4%
1Y-33.8%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Revenue grew 20.0% YoY.
Revenue (FY2025) $419M · FY2025
The read
Quality fundamentals and an attractive price line up (~208% below fair value) — the rarer case where both the business and the entry look good.
MIMEDX GROUP, INC. shows $419M in FY2025 revenue (+20.0% YoY), a 11.6% net margin, and 18.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $242M | $268M | $321M | $349M | $419M |
| Gross profit | $202M | $220M | $267M | $289M | $346M |
| Operating income | -$7.05M | -$14.7M | $37.1M | $58.9M | $63.9M |
| Net income | -$10.3M | -$30.2M | $58.2M | $42.4M | $48.6M |
| Diluted EPS | -$0.15 | -$0.33 | $0.37 | $0.28 | $0.32 |
| Net margin | -4.2% | -11.3% | 18.1% | 12.2% | 11.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$436M
EV / EBITDA5.5
EV / Sales1.0
EV / FCF6.1
P / FCF8.1
PEG (trailing)0.85
Earnings yield8.3%
FCF yield12.3%
Quality & risk
ROIC (est.)18.4%
Free cash flow$72.0M
Total debt$18.0M
Net cash$148M
Altman Z-Score6.48 safe
Piotroski F-Score5/9
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+0.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-242026-06-25open ↗8-KPeriod ending 2026-06-102026-06-16open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗DEFA14AFiling2026-04-29open ↗ARSPeriod ending 2025-12-312026-04-29open ↗DEF 14APeriod ending 2025-12-312026-04-29open ↗8-KPeriod ending 2026-04-292026-04-29open ↗10-QPeriod ending 2026-03-312026-04-29open ↗
Frequently asked
- Is MIMEDX GROUP, INC. (MDXG) a buy?
- MDXG currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 20.0% YoY.
- What is MDXG's fair value?
- A Modified-Graham model based on MDXG's SEC fundamentals estimates a fair value of about $12.10. It is an estimate from reported earnings, not a price target.
- Is MDXG overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, MDXG currently appears undervalued relative to its SEC-grounded earnings power.
- What is MIMEDX GROUP, INC.'s quality score?
- MDXG scores 81/100 (grade A-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001376339, latest 10-Q filed 2026-04-29) · EODHD · as of 6/26/2026, 6:22:51 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.